Interferon-alpha therapy for chronic myelogenous leukemia (Q40421360)

20 September 2017

1 reference

title

Interferon-alpha therapy for chronic myelogenous leukemia (English)

1 reference

20 September 2017

Wetzler M

1

1 reference

20 September 2017

Kantarjian H

series ordinal

2

1 reference

20 September 2017

Kurzrock R

series ordinal

3

1 reference

20 September 2017

Talpaz M

series ordinal

4

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 October 1995

1 reference

American Journal of Medicine

20 September 2017

1 reference

20 September 2017

99

1 reference

20 September 2017

4

1 reference

20 September 2017

402-411

1 reference

The molecular genetics of Philadelphia chromosome-positive leukemias

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

The interferons. Mechanisms of action and clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Evolving modalities of treatment with interferon alfa-2b for Ph1-positive chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Naloxone blocks the interferon-alpha induced changes in hypothalamic neuronal activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine Arabinoside.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Marrow transplantation for the treatment of chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Use of interferon alfa-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Interferon therapy for Ph1-positive chronic myelogenous leukaemia patients relapsing after T-cell depleted allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome-negative cells in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: Preliminary results of an open French multicentre randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980189-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)80189-2

1 reference

20 September 2017

1 reference